For therapeutic applications, BioPharmX has developed a novel anhydrous, hydrophilic topical delivery system. This delivery system uses a hydrophilic gel formulation that is rapidly absorbed into the skin rather than remaining on the surface, a common problem with lipophilic ointments and suspensions. Due to the nature of the platform design, it may be suitable for multiple APIs. The first molecule being developed using this delivery system is minocycline for both acne and rosacea indications. Minocycline was selected as the first API as it is the most commonly prescribed oral antibiotic for the treatment of these conditions due to its high effectiveness, anti-inflammatory properties, and relatively low antibiotic resistance rate.